A new clinical trial aims to find out if CBD is safe and effective when used alongside an anti-psychotic drug,
A previous study, published in the American Journal of Psychiatry, suggested that: “CBD had beneficial effects in patients with schizophrenia.”
It said that CBD “may represent a new class of treatment for the disorder.”
The phase two study is expected to include approximately 366 patients in the randomized, double blind trial.
The clinical trial is in the “recruiting patients” phase and expected to have completed results in June 2022.